免疫检查点抑制剂引发放射唤醒性肺炎的研究进展

Research progress of radiation recall pneumonitis caused by immune checkpoint inhibitors

目前肿瘤治疗进入了免疫治疗时代。但近年来发现,胸部放疗后应用免疫检查点抑制剂在起到协同抗肿瘤作用的同时,也会引发放射唤醒性肺炎(RRP)。RRP是一种少见的免疫相关不良反应,严重者甚至导致患者死亡。研究免疫检查点抑制剂引起RRP的相关机制以及影响因素,对加强RRP的认知管理以及降低RRP发生风险具有重要意义。

At present,tumor therapy has entered the era of immunotherapy.However,in recent years,it has been found that the application of immune checkpoint inhibitors after chest radiotherapy can not only play a synergistic anti-tumor effect,but also cause radiation recall pneumonitis(RRP).RRP is a rare immune-related adverse reaction,which even leads to death in severe cases.It is of great significance to study the mechanisms and influencing factors of RRP caused by immune checkpoint inhibitors for strengthening the cognitive management of RRP and reducing the risk of RRP.